THE API POWDER DIARIES

“The current problem has exposed some structural weaknesses from the EU’s medicines provide chain and a superior dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides mentioned. She recommended that supply chain challenges be tackled within an EU pharmaceutical strategy predicted to become released by